Pfizer Files for IPR of Two Biogen Patents Directed to Rituximab

In the past few days, Pfizer has filed petitions for IPR of two of Biogen’s patents related to rituximab:  IPR2017-01166 on U.S. Patent 8,329,172 and IPR2017-01167 on U.S. Patent 8,577,244.  According to the petitions, the patents are directed to methods of treating non-Hodgkin’s Lymphoma with rituximab.

The petitions are posted on our IPR Tracker page, along with other selected documents from IPRs of biologic patents.